Glaukos Corporation (GKOS)
Market Cap | 2.29B |
Revenue (ttm) | 284.88M |
Net Income (ttm) | -89.61M |
Shares Out | 47.70M |
EPS (ttm) | -1.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 325,546 |
Open | 48.06 |
Previous Close | 48.18 |
Day's Range | 47.15 - 48.29 |
52-Week Range | 33.33 - 64.49 |
Beta | 1.20 |
Analysts | Buy |
Price Target | 58.55 (+21.88%) |
Earnings Date | Feb 20, 2023 |
About GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; a... [Read more]
Financial Performance
In 2021, Glaukos's revenue was $294.01 million, an increase of 30.70% compared to the previous year's $224.96 million. Losses were -$49.59 million, -58.79% less than in 2020.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is $58.55, which is an increase of 21.88% from the latest price.
News

Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Here's Why Glaukos (GKOS) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Glaukos (GKOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio...

Glaukos Announces Participation in the Stephens Annual Investment Conference
ALISO VIEJO, Calif.

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Corporation Announces Third Quarter 2022 Financial Results
ALISO VIEJO, Calif.

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
ALISO VIEJO, Calif.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

(GKOS) – What's Going On With Glaukos Stock?
Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved...

Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

Why Is Glaukos (GKOS) Down 8.7% Since Last Earnings Report?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation
BOSTON , Aug. 29, 2022 /PRNewswire/ -- – Burns & Levinson is pleased to announce that it represented iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with development...

Glaukos Announces Participation in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

Glaukos Licenses Iveena's Investigational Keratoconus Therapy
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a...

Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.